NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $3.60 +0.06 (+1.69%) (As of 10:51 AM ET) Add Compare Share Share Today's Range$3.56▼$3.6550-Day Range$2.62▼$3.9652-Week Range$2.28▼$8.51Volume78,669 shsAverage Volume1.57 million shsMarket Capitalization$530.53 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Adaptive Biotechnologies alerts: Email Address Adaptive Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside92.1% Upside$6.80 Price TargetShort InterestBearish8.86% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.53Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.29) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.59 out of 5 starsMedical Sector231st out of 879 stocksBiological Products, Except Diagnostic Industry29th out of 150 stocks 3.3 Analyst's Opinion Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAdaptive Biotechnologies has received no research coverage in the past 90 days.Read more about Adaptive Biotechnologies' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.86% of the outstanding shares of Adaptive Biotechnologies have been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Adaptive Biotechnologies has recently decreased by 2.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Adaptive Biotechnologies is -0.79. Previous Next 1.4 News and Social Media Coverage News SentimentAdaptive Biotechnologies has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adaptive Biotechnologies this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.29) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Financial Markets DailyNYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech companyClick here for the company ticker About Adaptive Biotechnologies Stock (NASDAQ:ADPT)Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Read More ADPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADPT Stock News HeadlinesJune 29, 2024 | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down to $3.41May 31, 2024 | globenewswire.comAdaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid CongressJuly 8, 2024 | Financial Markets Daily (Ad)NYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech companyMay 29, 2024 | globenewswire.comAdaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 25, 2024 | finance.yahoo.comARK Invest's Cathie Wood Snags These 3 Bargains — Are They Right for Your Portfolio?May 24, 2024 | insidermonkey.comDoes Adaptive Biotechnologies Corporation (ADPT) Have Strong Growth Potential?May 23, 2024 | bizjournals.comAdaptive Sports Northwest's Jen Armbruster on making businesses more inclusive to those with disabilitiesMay 23, 2024 | investorplace.comMighty Mites: 3 Small-Cap Stocks Packing a Powerful PunchJuly 8, 2024 | Financial Markets Daily (Ad)NYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech companyMay 22, 2024 | venturebeat.comSkymel’s NeuroSplit™ Adaptive Inferencing Lets AI Companies Run the Latest GenAI Models – Even on Older GPUsMay 22, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtMay 15, 2024 | finance.yahoo.comAdaptive Biotechnologies Corporation (ADPT)May 9, 2024 | finance.yahoo.comAdaptive Biotechnologies First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | msn.comAdaptive Surf Championships return to Waikiki welcoming athletes from 18 countriesMay 8, 2024 | fool.comWhy Adaptive Biotechnologies Topped the Market TodayMay 8, 2024 | finance.yahoo.comAdaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comAdaptive Biotechnologies Corp (ADPT) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 8, 2024 | msn.comADPT Stock Earnings: Adaptive Biotechnologies Beats EPS, Beats Revenue for Q1 2024See More Headlines Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/07/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADPT CUSIPN/A CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees709Year Founded2009Price Target and Rating Average Stock Price Target$6.80 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+92.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-225,250,000.00 Net Margins-123.24% Pretax Margin-123.29% Return on Equity-56.58% Return on Assets-27.45% Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.35 Sales & Book Value Annual Sales$170.28 million Price / Sales3.06 Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book1.66Miscellaneous Outstanding Shares147,370,000Free Float138,231,000Market Cap$521.69 million OptionableOptionable Beta1.35 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Julie Rubinstein (Age 52)President & COO Comp: $721.04kDr. Harlan S. Robins Ph.D. (Age 51)Co-Founder & Chief Scientific Officer Comp: $711.09kMs. Stacy L. Taylor (Age 64)Senior VP, General Counsel & Corporate Secretary Ms. Mary Pat LancelottaSenior Vice President of MRD BioPharmaKey CompetitorsFluidigmNASDAQ:FLDMKodiak SciencesNASDAQ:KODIovance BiotherapeuticsNASDAQ:IOVABeam TherapeuticsNASDAQ:BEAMKymera TherapeuticsNASDAQ:KYMRView All CompetitorsInsiders & InstitutionsTidal Investments LLCBought 37,256 shares on 5/17/2024Ownership: 0.025%California State Teachers Retirement SystemSold 6,392 shares on 5/16/2024Ownership: 0.070%Lazard Asset Management LLCSold 15,786 shares on 5/15/2024Ownership: 0.119%Price T Rowe Associates Inc. MDSold 137,655 shares on 5/15/2024Ownership: 0.105%EntryPoint Capital LLCSold 8,394 shares on 5/14/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $4.90 at the beginning of the year. Since then, ADPT stock has decreased by 27.8% and is now trading at $3.54. View the best growth stocks for 2024 here. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.02. The firm's revenue for the quarter was up 11.2% on a year-over-year basis. What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO? 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Home Depot (HD). This page (NASDAQ:ADPT) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be h...Financial Markets Daily | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADPT Stock Alerts